// App-Quantinova.ai

P1037 : DOES EARLY INTERVENTION IN MYELOFIBROSIS IMPACT OUTCOMES? A POOLED ANALYSIS OF THE COMFORT I AND II STUDIES

Researchers

Presenter

  • Claire Harrison

Principal Investigators

  • Jean-Jacques Kiladjian

  • Alessandro M. Vannucchi

  • Ruben A. Mesa

  • Robyn M. Scherber

  • Srdan Verstovsek

Medical Centers

  • University of Texas MD Anderson Cancer Center, Houston, Texas, United States

  • Hôpital Saint-Louis, Assitance Publique – Hôpitaux de Paris, Université de Paris, Inserm,Paris,Francia

  • Incyte Corporation,Wilmington, DE,Stati Uniti

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • St Thomas' NHS Foundation Trust,London,Vereinigtes Königreich

  • Mays Cancer Institute at UT Health San Antonio MD Anderson,San Antonio,United States

  • Incyte Corporation,Wilmington, DE,États-unis

  • CRIMM, Center for

  • Hôpital Saint-Louis, Assitance Publique – Hôpitaux de Paris, Université de Paris, Inserm,Paris,France

  • Hôpital Saint-Louis, Assitance Publique – Hôpitaux de Paris, Université de Paris, Inserm,Paris,Francia

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Center for Research and Center for Research and Innovation of Myeloproliferative Neoplasms, AOU Careggi, University of Florence, Florence, Italy

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Incyte Corporation,Wilmington,Verenigde Staten

  • The University of Texas MD Anderson Cancer...

  • Mays Cancer Institute at UT Health San Antonio MD Anderson,San Antonio,Stati Uniti

  • Incyte Corporation,Wilmington, DE,Estados Unidos

  • Guy's and St. Thomas' NHS Foundation Trust, Guy's Hospital,London,United Kingdom

  • Hôpital Saint-Louis, Assitance Publique – Hôpitaux de Paris, Université de Paris, Inserm,Paris,Francia

  • Guy's and St. Thomas' NHS Foundation Trust, Guy's Hospital,London,Royaume-uni

  • Incyte Corporation, Wilmington, DE

  • Department of Leukemia,University of Texas MD Anderson Cancer Center,Houston,Vereinigte Staaten

  • Incyte Corporation,Wilmington, DE,Verenigde Staten

  • Mays Cancer Institute at UT Health San Antonio MD Anderson,San Antonio,Stati Uniti

  • Incyte Corporation,Wilmington,Verenigde Staten

  • Center for Research and Center for Research and Innovation of Myeloproliferative Neoplasms, AOU Careggi, University of Florence, Florence, Italy

  • Mays Cancer Institute at UT Health San Antonio MD Anderson,S

  • Mays Cancer Institute at UT Health San Antonio MD Anderson,San Antonio,Stati Uniti

  • Center for Research and Center for Research and Innovation of Myeloproliferative Neoplasms, AOU Careggi, University of Florence, Florence, Italy

Locations

  • United Kingdom

  • France

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

  • Oncology (ONC)

Disease

  • Thrombocytopenia

  • Myelofibrosis

  • Anemia

Biomarkers

  • N-Acylethanolamine acid amidase

  • Sustained virological response

Drug/Treatment

  • Ruxolitinib phosphate

Outcome

  • N/A

Study Design

  • Randomized

  • Cross Over

Phase

  • III

Study Id's

  • NCT00952289

  • NCT00934544

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved